Nifty
:
22600.00
Sensex
:
73123.83
-87.65 (-0.39%)
-125.56 (-0.17%)
Nifty
Sensex
:
:
22600.00
73123.83
-87.65 (-0.39%)
-125.56 (-0.17%)

Jubilant Pharmova Ltd.

Chemicals

Rating :
57/99

BSE: 530019 | NSE: JUBLPHARMA

NSE BSE
938.30
23-Oct-2026
  • Open
  • High
  • Low
  • Previous Close
  •  932
  •  944.8
  •  895.1
  •  932.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  142183
  •  130736543.9
  •  1183
  •  786.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,938.18
  • 42.43
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,890.08
  • 0.53%
  • 2.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.68%
  • 3.09%
  • 17.03%
  • FII
  • DII
  • Others
  • 15.37%
  • 10.49%
  • 6.34%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.51
  • 6.20
  • 7.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.65
  • 1.73
  • 6.94

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -3.61
  • -0.76
  • 72.90

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.48
  • 30.20
  • 34.11

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.92
  • 1.89
  • 2.35

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.31
  • 11.98
  • 14.48

Earnings Forecasts:

(Updated: 24-10-2026)
Description
2026
2027
2028
2029
Adj EPS
25.15
28.1
50.55
-
P/E Ratio
37.31
33.39
18.56
-
Revenue
8279.6
9407.73
10679.2
-
EBITDA
1259.8
1425.4
1861.13
-
Net Income
398.5
448.1
804.85
-
ROA
2.82
-
-
-
P/B Ratio
2.11
1.97
1.80
-
ROE
5.97
6.15
10.25
-
FCFF
-436.2
393.4
443.15
-
FCFF Yield
-2.54
2.29
2.58
-
Net Debt
2347.1
2270.6
2403.5
-
BVPS
445.21
476.15
520
-

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
2,229.40
1,900.70
17.29%
2,290.00
1,928.80
18.73%
2,122.50
1,821.70
16.51%
1,966.40
1,752.30
12.22%
Expenses
1,981.40
1,611.10
22.98%
1,950.70
1,583.40
23.20%
1,833.00
1,534.30
19.47%
1,625.00
1,462.90
11.08%
EBITDA
248.00
289.60
-14.36%
339.30
345.40
-1.77%
289.50
287.40
0.73%
341.40
289.40
17.97%
EBIDTM
11.12%
15.24%
14.82%
17.91%
13.64%
15.78%
17.36%
16.52%
Other Income
19.90
12.00
65.83%
23.70
11.90
99.16%
20.50
9.20
122.83%
9.80
21.70
-54.84%
Interest
54.20
49.00
10.61%
56.50
52.70
7.21%
56.10
55.60
0.90%
50.20
61.00
-17.70%
Depreciation
127.30
98.10
29.77%
116.80
95.20
22.69%
120.70
91.30
32.20%
104.80
91.40
14.66%
PBT
86.40
154.50
-44.08%
176.00
206.10
-14.60%
93.50
130.80
-28.52%
190.40
144.50
31.76%
Tax
30.00
51.90
-42.20%
56.70
54.70
3.66%
37.60
29.80
26.17%
70.40
41.90
68.02%
PAT
56.40
102.60
-45.03%
119.30
151.40
-21.20%
55.90
101.00
-44.65%
120.00
102.60
16.96%
PATM
2.53%
5.40%
5.21%
7.85%
2.63%
5.54%
6.10%
5.86%
EPS
3.58
6.51
-45.01%
7.56
9.72
-22.22%
3.54
6.39
-44.60%
7.61
6.51
16.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
8,608.30
8,279.60
7,234.50
6,702.90
6,281.70
6,130.16
6,098.53
5,975.79
9,110.82
7,517.84
5,861.43
Net Sales Growth
16.27%
14.45%
7.93%
6.71%
2.47%
0.52%
2.05%
-34.41%
21.19%
28.26%
 
Cost Of Goods Sold
2,774.80
2,644.30
2,317.00
2,140.70
1,877.90
1,488.01
1,536.01
1,455.18
3,521.84
2,862.51
2,002.74
Gross Profit
5,833.50
5,635.30
4,917.50
4,562.20
4,403.80
4,642.16
4,562.52
4,520.61
5,588.98
4,655.33
3,858.69
GP Margin
67.77%
68.06%
67.97%
68.06%
70.11%
75.73%
74.81%
75.65%
61.34%
61.92%
65.83%
Total Expenditure
7,390.10
7,019.80
6,060.80
5,802.10
5,505.50
4,973.83
4,702.07
4,427.84
7,371.81
5,999.45
4,516.14
Power & Fuel Cost
-
155.50
154.30
148.90
166.70
134.30
105.79
112.21
466.38
424.91
333.66
% Of Sales
-
1.88%
2.13%
2.22%
2.65%
2.19%
1.73%
1.88%
5.12%
5.65%
5.69%
Employee Cost
-
2,700.60
2,267.90
2,216.00
2,166.00
2,043.39
1,922.88
1,843.22
1,925.96
1,555.88
1,230.93
% Of Sales
-
32.62%
31.35%
33.06%
34.48%
33.33%
31.53%
30.84%
21.14%
20.70%
21.00%
Manufacturing Exp.
-
650.00
546.00
523.20
581.10
562.32
449.40
362.15
552.26
485.98
428.84
% Of Sales
-
7.85%
7.55%
7.81%
9.25%
9.17%
7.37%
6.06%
6.06%
6.46%
7.32%
General & Admin Exp.
-
586.00
495.20
475.00
464.10
432.34
387.92
416.80
540.75
354.56
280.98
% Of Sales
-
7.08%
6.84%
7.09%
7.39%
7.05%
6.36%
6.97%
5.94%
4.72%
4.79%
Selling & Distn. Exp.
-
205.70
205.80
214.30
161.60
209.71
177.15
194.71
267.70
247.85
185.79
% Of Sales
-
2.48%
2.84%
3.20%
2.57%
3.42%
2.90%
3.26%
2.94%
3.30%
3.17%
Miscellaneous Exp.
-
77.70
74.60
84.00
88.10
103.77
122.93
43.57
96.92
67.76
185.79
% Of Sales
-
0.94%
1.03%
1.25%
1.40%
1.69%
2.02%
0.73%
1.06%
0.90%
0.91%
EBITDA
1,218.20
1,259.80
1,173.70
900.80
776.20
1,156.33
1,396.46
1,547.95
1,739.01
1,518.39
1,345.29
EBITDA Margin
14.15%
15.22%
16.22%
13.44%
12.36%
18.86%
22.90%
25.90%
19.09%
20.20%
22.95%
Other Income
73.90
66.00
56.80
68.70
38.30
11.29
17.64
37.41
35.74
40.03
24.86
Interest
217.00
211.80
240.30
272.30
188.20
145.49
184.10
199.71
219.81
284.28
341.11
Depreciation
469.60
440.40
368.60
381.90
554.00
381.70
348.95
339.84
370.90
415.05
291.40
PBT
546.30
673.60
621.60
315.30
72.30
640.43
881.05
1,045.81
1,184.04
859.08
737.64
Tax
194.70
216.60
144.30
97.80
92.70
217.43
297.22
335.10
326.80
224.66
163.02
Tax Rate
35.64%
35.25%
14.71%
66.80%
598.06%
33.95%
34.57%
33.08%
36.16%
26.15%
22.10%
PAT
351.60
398.50
839.40
77.10
-61.00
413.94
574.12
677.77
574.46
642.81
575.66
PAT before Minority Interest
352.30
397.50
836.30
72.70
-64.90
413.02
573.86
677.77
577.01
634.42
574.63
Minority Interest
0.70
1.00
3.10
4.40
3.90
0.92
0.26
0.00
-2.55
8.39
1.03
PAT Margin
4.08%
4.81%
11.60%
1.15%
-0.97%
6.75%
9.41%
11.34%
6.31%
8.55%
9.82%
PAT Growth
-23.16%
-52.53%
988.72%
-
-
-27.90%
-15.29%
17.98%
-10.63%
11.66%
 
EPS
22.07
25.02
52.69
4.84
-3.83
25.98
36.04
42.55
36.06
40.35
36.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
7,092.80
6,255.00
5,433.90
5,399.30
5,318.56
4,741.49
5,603.88
4,808.92
4,086.53
3,436.04
Share Capital
15.80
15.80
15.80
15.90
15.92
15.92
15.93
15.93
15.58
15.57
Total Reserves
7,057.80
6,224.30
5,403.60
5,377.20
5,298.98
4,724.75
5,587.95
4,792.94
4,070.78
3,419.98
Non-Current Liabilities
5,631.10
4,095.80
4,005.70
3,765.00
2,921.59
2,973.05
4,087.52
4,420.21
3,417.47
3,826.06
Secured Loans
378.00
237.20
299.30
265.10
200.94
20.78
728.92
811.65
729.88
1,207.91
Unsecured Loans
2,593.70
1,913.10
2,867.80
2,845.30
2,263.30
2,543.19
3,010.76
3,431.24
2,317.93
2,297.13
Long Term Provisions
159.50
119.10
100.10
92.20
95.67
94.01
150.75
114.35
107.08
80.69
Current Liabilities
2,538.90
2,164.60
1,889.00
1,772.40
1,591.60
1,048.83
2,619.01
2,089.73
2,004.69
1,684.04
Trade Payables
1,234.10
1,004.80
856.30
821.30
567.74
520.48
1,090.27
1,020.13
1,136.16
749.49
Other Current Liabilities
1,027.90
844.00
732.80
552.10
838.52
371.73
674.21
473.57
505.87
572.70
Short Term Borrowings
162.50
219.00
196.50
258.30
64.00
20.00
649.89
499.71
244.85
255.60
Short Term Provisions
114.40
96.80
103.40
140.70
121.34
136.62
204.64
96.31
117.81
106.24
Total Liabilities
15,265.60
12,499.10
11,315.80
10,929.20
9,829.59
8,763.40
12,310.41
11,318.96
9,457.17
8,898.75
Net Block
6,965.60
5,175.90
5,091.20
5,183.30
4,870.61
4,608.75
6,339.97
5,648.38
5,400.55
5,106.73
Gross Block
10,167.20
7,822.90
7,868.90
7,368.00
6,758.89
6,089.57
8,041.80
6,905.50
6,288.86
5,672.38
Accumulated Depreciation
3,201.60
2,647.00
2,777.70
2,184.70
1,888.28
1,480.83
1,701.83
1,257.12
888.31
565.66
Non Current Assets
11,156.30
8,921.80
7,439.70
7,166.80
6,320.40
5,810.90
7,272.06
6,734.16
6,267.41
5,950.63
Capital Work in Progress
4,040.40
3,630.00
2,103.10
1,561.50
1,089.57
896.99
768.39
901.43
670.97
683.78
Non Current Investment
61.40
43.50
42.20
256.40
238.60
240.96
69.36
115.11
123.52
102.71
Long Term Loans & Adv.
66.00
54.10
191.90
161.50
117.64
62.84
86.81
68.59
71.79
56.32
Other Non Current Assets
22.90
18.30
11.30
4.10
3.98
1.35
7.53
0.66
0.58
1.08
Current Assets
4,109.30
3,509.80
3,632.20
3,762.40
3,509.19
2,952.50
5,038.35
4,584.80
3,189.76
2,948.12
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,231.50
1,129.20
1,289.60
1,380.50
1,254.87
1,129.38
1,845.38
1,417.39
1,391.39
1,220.40
Sundry Debtors
1,069.60
891.50
915.90
961.20
927.99
819.90
1,293.22
1,271.55
1,130.76
1,005.30
Cash & Bank
1,267.60
1,088.80
956.80
1,014.30
984.24
671.32
1,399.87
1,370.41
248.79
459.63
Other Current Assets
540.60
154.00
241.90
135.10
342.10
331.90
499.89
525.44
418.81
262.79
Short Term Loans & Adv.
321.00
246.30
228.00
271.30
231.17
205.13
357.68
396.93
313.03
189.04
Net Current Assets
1,570.40
1,345.20
1,743.20
1,990.00
1,917.59
1,903.67
2,419.34
2,495.07
1,185.06
1,264.08
Total Assets
15,265.60
12,431.60
11,071.90
10,929.20
9,829.59
8,763.40
12,310.41
11,318.96
9,457.17
8,898.75

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
1,226.80
1,072.10
971.30
660.70
837.54
1,784.27
1,542.94
1,121.51
1,303.20
1,268.49
PBT
614.10
980.60
170.50
27.80
630.45
1,212.01
1,210.53
903.81
859.08
737.64
Adjustment
682.70
218.10
755.40
782.90
579.47
716.48
760.74
861.53
687.81
637.90
Changes in Working Capital
139.40
111.80
253.10
54.30
-178.29
249.90
-179.67
-300.53
14.15
36.88
Cash after chg. in Working capital
1,436.20
1,310.50
1,179.00
865.00
1,031.63
2,178.39
1,791.60
1,464.82
1,561.04
1,412.42
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-209.40
-238.40
-207.70
-204.30
-194.09
-394.12
-248.66
-343.31
-257.84
-143.94
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,260.00
487.70
-607.90
-544.40
-380.37
-739.01
-327.00
-1,011.84
-617.70
-450.39
Net Fixed Assets
887.70
-9.50
-51.10
-92.16
-752.97
2,205.67
-249.11
-305.67
-147.58
-115.33
Net Investments
-519.00
-0.10
-0.30
-10.85
0.23
118.05
-0.14
-57.59
3.34
-0.39
Others
-1,628.70
497.30
-556.50
-441.39
372.37
-3,062.73
-77.75
-648.58
-473.46
-334.67
Cash from Financing Activity
94.90
-1,452.70
-432.50
-156.70
-32.60
-1,709.39
-1,050.37
657.43
-901.13
-685.87
Net Cash Inflow / Outflow
61.70
107.10
-69.10
-40.40
424.57
-664.13
165.56
767.10
-215.63
132.22
Opening Cash & Equivalents
1,088.30
956.40
1,013.90
983.80
501.96
1,230.81
1,005.40
244.18
456.44
339.27
Closing Cash & Equivalent
1,267.10
1,088.30
956.40
1,013.90
983.82
501.96
1,230.81
1,005.40
244.18
456.44

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
447.70
394.94
343.00
339.19
333.91
297.84
351.83
301.93
262.33
220.61
ROA
2.86%
7.02%
0.65%
-0.63%
4.44%
5.34%
7.60%
5.55%
6.91%
6.52%
ROE
5.97%
14.35%
1.34%
-1.21%
8.21%
10.88%
17.25%
12.97%
16.87%
17.95%
ROCE
8.69%
13.92%
5.02%
2.53%
9.97%
11.89%
15.07%
13.06%
15.21%
14.44%
Fixed Asset Turnover
0.97
0.97
0.88
0.89
0.95
0.87
1.23
1.38
1.26
1.09
Receivable days
40.92
43.15
51.11
54.89
52.04
63.24
51.13
48.12
51.58
59.43
Inventory Days
49.26
57.75
72.70
76.56
70.98
89.02
65.05
56.26
63.07
73.64
Payable days
154.52
146.59
143.02
134.99
133.47
191.38
58.75
55.42
56.86
54.84
Cash Conversion Cycle
-64.33
-45.69
-19.21
-3.54
-10.45
-39.12
57.43
48.96
57.79
78.23
Total Debt/Equity
0.46
0.39
0.63
0.63
0.55
0.55
0.83
1.01
0.85
1.18
Interest Cover
3.90
5.08
1.63
1.15
5.33
5.67
5.21
5.11
4.02
3.16

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Abakkus Asset Managers buys 0.69% stake in Jubilant Pharmova
    13th Oct 2026, 14:47 PM

    Abakkus Four2Eight Opportunities Fund has bought 11 lakh shares of the company for around Rs 100.65 crore

    Read More
  • Jubilant Pharmova gets nod to raise up to Rs 800 crore via NCDs
    12th Oct 2026, 14:26 PM

    The Board of Directors of the Company, at its meeting held on October 12, 2026, has, inter alia, considered and approved the same

    Read More
  • Jubilant Pharmova's arm to invest 94.5 million Canadian Dollar to double RUBY-FILL capacity
    9th Oct 2026, 10:59 AM

    The Government of Canada will provide a financial support of 23.8 million Canadian Dollar to this project

    Read More
  • Jubilant Pharmova gets USFDA's approval for new Isolator based fill and finish line at Spokane Facility
    24th Aug 2026, 11:14 AM

    Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.